Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.
Marketing Status Prescription; Discontinued
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 70436-012; 70436-013; 50090-4806; 0054-0401; 46708-152; 70518-3195; 68382-469; 0591-3659; 71335-1815; 0054-0603; 70436-036; 71335-1753; 51407-023; 0591-4060; 50090-4388; 63304-191; 0591-3660; 14501-0068; 46708-153; 60687-607; 70771-1311; 68382-741; 71335-1975; 0054-0400; 51407-022; 63304-192; 63629-7524; 71335-1700; 70771-1312; 69766-025
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disorientation19.13.01.002; 17.02.05.0150.000846%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.002961%
Dizziness24.06.02.007; 02.01.02.004; 17.02.05.0030.024533%
Drug dependence19.07.02.0090.002538%Not Available
Drug hypersensitivity10.01.01.0010.019034%Not Available
Drug withdrawal convulsions08.06.02.003; 17.12.03.0160.000846%Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.0040.013959%Not Available
Dry mouth07.06.01.0020.002961%
Dry skin23.03.03.001--
Dysarthria19.19.03.001; 17.02.08.0010.000846%
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.0060.002115%
Dysphagia07.01.06.0030.003807%
Dysphoria19.04.02.0040.001269%Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Dystonia17.01.03.0010.001269%Not Available
Ear disorder04.03.01.001--Not Available
Ejaculation delayed21.03.01.001--Not Available
Ejaculation disorder21.03.01.002--
Ejaculation failure21.03.01.003--Not Available
Electrocardiogram QT prolonged13.14.05.004--
Emotional disorder19.04.02.0050.007614%Not Available
Eosinophilic pneumonia22.01.01.004; 01.02.04.003--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000846%
Euphoric mood19.04.02.0060.001692%
Extrapyramidal disorder17.01.02.007--
Eye disorder06.08.03.0010.001692%Not Available
Facial pain08.01.08.0120.001269%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 11 Pages